Genenta Science S.p.A.

Develops cell & gene therapies using engineered stem cells to treat solid tumors.

GNTA | NDAQ

Overview

Corporate Details

ISIN(s):: N/A
LEI:
Country:: United States of America
Address:: OLGETTINA, NO. 58, 20132 MILAN
Website:: https://www.genenta.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Genenta Science S.p.A. is a clinical-stage immuno-oncology company developing proprietary cell and gene therapies for the treatment of solid tumors. The company's technology is centered on engineering a patient's own hematopoietic stem cells using a lentiviral vector to combat cancer. Its lead candidate, Temferon, is designed to make tumors visible to the immune system by reprogramming the tumor microenvironment and breaking immune tolerance. Genenta has completed a Phase 1 clinical trial in Glioblastoma Multiforme and has initiated a Phase 1/2a study in metastatic Renal Cell Carcinoma. The treatments are designed as one-time monotherapies that also have the potential to be used in combination to enhance the efficacy of other therapeutics, such as immune checkpoint inhibitors.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Genenta Science S.p.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Genenta Science S.p.A.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Genenta Science S.p.A. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Calliditas Therapeutics Develops and commercializes novel treatments for rare renal and hepatic diseases like IgA nephropathy.	Sweden	CALTX
CALTH. Inc Develops AI-powered rapid diagnostic solutions for point-of-care and self-testing.	South Korea	402420
CAMBRIDGE NUTRITIONAL SCIENCES PLC Develops and manufactures diagnostic tests for food sensitivity and gut health.	United Kingdom	CNSL
Camp4 Therapeutics Corp Developing RNA-based therapies to upregulate genes for rare metabolic and CNS disorders.	United States of America	CAMP
Camurus Develops long-acting medicines for severe chronic diseases using advanced drug delivery.	Sweden	CAMX
CanBas Co.,Ltd. Clinical-stage biopharma developing novel cancer drugs aiming for fewer side effects.	Japan	4575
Candel Therapeutics, Inc. Developing off-the-shelf viral immunotherapies to help the immune system fight solid tumors.	United States of America	CADL
Can-Fite BioPharma Ltd. Clinical-stage biopharma developing oral drugs for cancer, inflammatory, liver & metabolic diseases.	United States of America	CANF
Can-Fite BioPharma Ltd. Develops oral small-molecule drugs targeting A3AR for oncology and inflammatory diseases.	Israel	CANF
Cannovum Cannabis AG Importer & producer of medical cannabis, expanding into recreational cultivation infrastructure.	Germany	27N0